Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma | Zendy

Lijuan Li | Zendy; Difei Chen | Zendy; Guofeng Wu | Zendy; Weijie Guan | Zendy; Zheng Zhu | Zendy; Yiqian Liu | Zendy; Guoying Gao | Zendy; Yinyin Qin | Zendy; Nanshan Zhong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma

Author(s) -

Lijuan Li,

Difei Chen,

Guofeng Wu,

Weijie Guan,

Zheng Zhu,

Yiqian Liu,

Guoying Gao,

Yinyin Qin,

Nanshan Zhong

Publication year - 2018

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2018.07.09

Subject(s) - bevacizumab , medicine , incidence (geometry) , oncology , lung cancer , odds ratio , adverse effect , cochrane library , meta analysis , gastroenterology , chemotherapy , physics , optics

Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF), is effective for the treatment of advanced non-small cell lung cancer (NSCLC). However, severe adverse events (AEs) have been reported in NSCLC patients treated with bevacizumab. Currently, the contribution of Bevacizumab to thromboembolism is still controversial. We conducted a study to determine the overall risk and incidence of thromboembolism with bevacizumab in NSCLC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research